Loading…

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes. It...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2019-07, Vol.3 (13), p.2013-2021
Main Authors: Barraclough, Allison, Alzahrani, Musa, Ettrup, Marianne Schmidt, Bishton, Mark, van Vliet, Chris, Farinha, Pedro, Gould, Clare, Birch, Simone, Sehn, Laurie H., Sovani, Vishakha, Ward, Mitchell Steven, Augustson, Bradley, Biccler, Jorne, Connors, Joseph M., Scott, David W., Gandhi, Maher K., Savage, Kerry J., El-Galaly, Tarec, Villa, Diego, Cheah, Chan Yoon
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183
cites cdi_FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183
container_end_page 2021
container_issue 13
container_start_page 2013
container_title Blood advances
container_volume 3
creator Barraclough, Allison
Alzahrani, Musa
Ettrup, Marianne Schmidt
Bishton, Mark
van Vliet, Chris
Farinha, Pedro
Gould, Clare
Birch, Simone
Sehn, Laurie H.
Sovani, Vishakha
Ward, Mitchell Steven
Augustson, Bradley
Biccler, Jorne
Connors, Joseph M.
Scott, David W.
Gandhi, Maher K.
Savage, Kerry J.
El-Galaly, Tarec
Villa, Diego
Cheah, Chan Yoon
description In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes. It is unclear whether these variables remain prognostic in stage I/II patients. In this retrospective study, we evaluated the prognostic impact of cell of origin (COO), as well as dual-expressor (DE) status and molecular double-hit (DH) status, in stage I/II DLBCL by positron emission tomography with computed tomography (PET-CT). A total of 211 patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimens, with or without radiotherapy, was included. The median follow-up in the entire cohort was 4 years (range, 0.4-9.4), with estimated 4-year progression-free survival (PFS) and overall survival (OS) rates of 85% (95% confidence interval [CI], 79-89) and 88% (95% CI, 83-92), respectively. By univariable analysis, DE (PFS: hazard ratio [HR], 1.27; 95% CI, 0.58-2.81, P = .55 and OS: HR, 1.40; 95% CI, 0.60-3.30; P = .44), DH (PFS: HR, 1.21; 95% CI, 0.27-5.31; P = .80 and OS: HR, 0.61; 95% CI, 0.08-4.73; P = .64), and non-GCB status (PFS: HR, 1.59; 95% CI, 0.83-3.03; P = .16 and OS: HR, 1.80; 95% CI, 0.89-3.67; P = .10) were associated with poorer outcomes. In patients with PET-CT–defined stage I/II DLBCL treated with R-CHOP–like therapy, with or without radiation, COO and DE and DH status were not significantly associated with inferior PFS or OS. •In early-stage DLBCL, COO and DE/DH status may not confer an inferior prognosis.•Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year PFS and OS rates of 85% and 88%. [Display omitted]
doi_str_mv 10.1182/bloodadvances.2019000251
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4ba1f4d6c89a4639a9f66dedff959652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952920306686</els_id><doaj_id>oai_doaj_org_article_4ba1f4d6c89a4639a9f66dedff959652</doaj_id><sourcerecordid>2254506935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183</originalsourceid><addsrcrecordid>eNqFUk1v1DAUjBCIVqV_AfnIZbv-iJ2YAxJN-Yi0aC9w4GR57ZetqyQOthPUf4-XLQt74mTLnpn33swrCkTwDSE1Xe967622ix4NxBuKicQYU06eFZe0rNhKclY9P92pvCiuY3zIGFIJxiV9WVwwQmtOanlZLM12i_Ro0Zfvzfq22VAUk05zRNaj0Sc0BbDOJOTnZPwASA9-3KNJJwdjiuinS_cHxh5Qu25bdLfJGm-RRgFS8HECk9wCaJj75ExmQMjo2T6-Kl50uo9w_XReFd8-fvjafF5ttp_a5v1mZXjJ04p1UlYUOBdVZ0AaZkxlSsw5waSU2BCrWdXhrrY13fFai7ISNdMCeMWZJDW7KtqjrvX6QU3BDTo8Kq-d-v3gw17pkFvrQZU7TbrSClNLXQomteyEsGC7TnIpOM1a745a07wbwB7GCbo_Ez3_Gd292vtFCUEEFTwLvHkSCP7HDDGpwUUDfa9H8HNUlOahsZDsAK2PUJNdjAG6UxmC1WEL1NkWqL9bkKmv_23zRPyTeQbcHgGQjV8cBBVNTtPkoEPOKzvj_l_lF7JxyJA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2254506935</pqid></control><display><type>article</type><title>COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study</title><source>ScienceDirect (Online service)</source><source>PubMed Central</source><creator>Barraclough, Allison ; Alzahrani, Musa ; Ettrup, Marianne Schmidt ; Bishton, Mark ; van Vliet, Chris ; Farinha, Pedro ; Gould, Clare ; Birch, Simone ; Sehn, Laurie H. ; Sovani, Vishakha ; Ward, Mitchell Steven ; Augustson, Bradley ; Biccler, Jorne ; Connors, Joseph M. ; Scott, David W. ; Gandhi, Maher K. ; Savage, Kerry J. ; El-Galaly, Tarec ; Villa, Diego ; Cheah, Chan Yoon</creator><creatorcontrib>Barraclough, Allison ; Alzahrani, Musa ; Ettrup, Marianne Schmidt ; Bishton, Mark ; van Vliet, Chris ; Farinha, Pedro ; Gould, Clare ; Birch, Simone ; Sehn, Laurie H. ; Sovani, Vishakha ; Ward, Mitchell Steven ; Augustson, Bradley ; Biccler, Jorne ; Connors, Joseph M. ; Scott, David W. ; Gandhi, Maher K. ; Savage, Kerry J. ; El-Galaly, Tarec ; Villa, Diego ; Cheah, Chan Yoon</creatorcontrib><description>In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes. It is unclear whether these variables remain prognostic in stage I/II patients. In this retrospective study, we evaluated the prognostic impact of cell of origin (COO), as well as dual-expressor (DE) status and molecular double-hit (DH) status, in stage I/II DLBCL by positron emission tomography with computed tomography (PET-CT). A total of 211 patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimens, with or without radiotherapy, was included. The median follow-up in the entire cohort was 4 years (range, 0.4-9.4), with estimated 4-year progression-free survival (PFS) and overall survival (OS) rates of 85% (95% confidence interval [CI], 79-89) and 88% (95% CI, 83-92), respectively. By univariable analysis, DE (PFS: hazard ratio [HR], 1.27; 95% CI, 0.58-2.81, P = .55 and OS: HR, 1.40; 95% CI, 0.60-3.30; P = .44), DH (PFS: HR, 1.21; 95% CI, 0.27-5.31; P = .80 and OS: HR, 0.61; 95% CI, 0.08-4.73; P = .64), and non-GCB status (PFS: HR, 1.59; 95% CI, 0.83-3.03; P = .16 and OS: HR, 1.80; 95% CI, 0.89-3.67; P = .10) were associated with poorer outcomes. In patients with PET-CT–defined stage I/II DLBCL treated with R-CHOP–like therapy, with or without radiation, COO and DE and DH status were not significantly associated with inferior PFS or OS. •In early-stage DLBCL, COO and DE/DH status may not confer an inferior prognosis.•Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year PFS and OS rates of 85% and 88%. [Display omitted]</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2019000251</identifier><identifier>PMID: 31285189</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Lymphoid Neoplasia</subject><ispartof>Blood advances, 2019-07, Vol.3 (13), p.2013-2021</ispartof><rights>2019 American Society of Hematology</rights><rights>2019 by The American Society of Hematology.</rights><rights>2019 by The American Society of Hematology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183</citedby><cites>FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183</cites><orcidid>0000-0002-4625-3009 ; 0000-0003-1000-5393 ; 0000-0001-7988-1565 ; 0000-0002-4406-380X ; 0000-0001-9364-9391 ; 0000-0001-6058-1036 ; 0000-0002-3043-9503</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6616265/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2473952920306686$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31285189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barraclough, Allison</creatorcontrib><creatorcontrib>Alzahrani, Musa</creatorcontrib><creatorcontrib>Ettrup, Marianne Schmidt</creatorcontrib><creatorcontrib>Bishton, Mark</creatorcontrib><creatorcontrib>van Vliet, Chris</creatorcontrib><creatorcontrib>Farinha, Pedro</creatorcontrib><creatorcontrib>Gould, Clare</creatorcontrib><creatorcontrib>Birch, Simone</creatorcontrib><creatorcontrib>Sehn, Laurie H.</creatorcontrib><creatorcontrib>Sovani, Vishakha</creatorcontrib><creatorcontrib>Ward, Mitchell Steven</creatorcontrib><creatorcontrib>Augustson, Bradley</creatorcontrib><creatorcontrib>Biccler, Jorne</creatorcontrib><creatorcontrib>Connors, Joseph M.</creatorcontrib><creatorcontrib>Scott, David W.</creatorcontrib><creatorcontrib>Gandhi, Maher K.</creatorcontrib><creatorcontrib>Savage, Kerry J.</creatorcontrib><creatorcontrib>El-Galaly, Tarec</creatorcontrib><creatorcontrib>Villa, Diego</creatorcontrib><creatorcontrib>Cheah, Chan Yoon</creatorcontrib><title>COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes. It is unclear whether these variables remain prognostic in stage I/II patients. In this retrospective study, we evaluated the prognostic impact of cell of origin (COO), as well as dual-expressor (DE) status and molecular double-hit (DH) status, in stage I/II DLBCL by positron emission tomography with computed tomography (PET-CT). A total of 211 patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimens, with or without radiotherapy, was included. The median follow-up in the entire cohort was 4 years (range, 0.4-9.4), with estimated 4-year progression-free survival (PFS) and overall survival (OS) rates of 85% (95% confidence interval [CI], 79-89) and 88% (95% CI, 83-92), respectively. By univariable analysis, DE (PFS: hazard ratio [HR], 1.27; 95% CI, 0.58-2.81, P = .55 and OS: HR, 1.40; 95% CI, 0.60-3.30; P = .44), DH (PFS: HR, 1.21; 95% CI, 0.27-5.31; P = .80 and OS: HR, 0.61; 95% CI, 0.08-4.73; P = .64), and non-GCB status (PFS: HR, 1.59; 95% CI, 0.83-3.03; P = .16 and OS: HR, 1.80; 95% CI, 0.89-3.67; P = .10) were associated with poorer outcomes. In patients with PET-CT–defined stage I/II DLBCL treated with R-CHOP–like therapy, with or without radiation, COO and DE and DH status were not significantly associated with inferior PFS or OS. •In early-stage DLBCL, COO and DE/DH status may not confer an inferior prognosis.•Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year PFS and OS rates of 85% and 88%. [Display omitted]</description><subject>Lymphoid Neoplasia</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFUk1v1DAUjBCIVqV_AfnIZbv-iJ2YAxJN-Yi0aC9w4GR57ZetqyQOthPUf4-XLQt74mTLnpn33swrCkTwDSE1Xe967622ix4NxBuKicQYU06eFZe0rNhKclY9P92pvCiuY3zIGFIJxiV9WVwwQmtOanlZLM12i_Ro0Zfvzfq22VAUk05zRNaj0Sc0BbDOJOTnZPwASA9-3KNJJwdjiuinS_cHxh5Qu25bdLfJGm-RRgFS8HECk9wCaJj75ExmQMjo2T6-Kl50uo9w_XReFd8-fvjafF5ttp_a5v1mZXjJ04p1UlYUOBdVZ0AaZkxlSsw5waSU2BCrWdXhrrY13fFai7ISNdMCeMWZJDW7KtqjrvX6QU3BDTo8Kq-d-v3gw17pkFvrQZU7TbrSClNLXQomteyEsGC7TnIpOM1a745a07wbwB7GCbo_Ez3_Gd292vtFCUEEFTwLvHkSCP7HDDGpwUUDfa9H8HNUlOahsZDsAK2PUJNdjAG6UxmC1WEL1NkWqL9bkKmv_23zRPyTeQbcHgGQjV8cBBVNTtPkoEPOKzvj_l_lF7JxyJA</recordid><startdate>20190709</startdate><enddate>20190709</enddate><creator>Barraclough, Allison</creator><creator>Alzahrani, Musa</creator><creator>Ettrup, Marianne Schmidt</creator><creator>Bishton, Mark</creator><creator>van Vliet, Chris</creator><creator>Farinha, Pedro</creator><creator>Gould, Clare</creator><creator>Birch, Simone</creator><creator>Sehn, Laurie H.</creator><creator>Sovani, Vishakha</creator><creator>Ward, Mitchell Steven</creator><creator>Augustson, Bradley</creator><creator>Biccler, Jorne</creator><creator>Connors, Joseph M.</creator><creator>Scott, David W.</creator><creator>Gandhi, Maher K.</creator><creator>Savage, Kerry J.</creator><creator>El-Galaly, Tarec</creator><creator>Villa, Diego</creator><creator>Cheah, Chan Yoon</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4625-3009</orcidid><orcidid>https://orcid.org/0000-0003-1000-5393</orcidid><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0002-4406-380X</orcidid><orcidid>https://orcid.org/0000-0001-9364-9391</orcidid><orcidid>https://orcid.org/0000-0001-6058-1036</orcidid><orcidid>https://orcid.org/0000-0002-3043-9503</orcidid></search><sort><creationdate>20190709</creationdate><title>COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study</title><author>Barraclough, Allison ; Alzahrani, Musa ; Ettrup, Marianne Schmidt ; Bishton, Mark ; van Vliet, Chris ; Farinha, Pedro ; Gould, Clare ; Birch, Simone ; Sehn, Laurie H. ; Sovani, Vishakha ; Ward, Mitchell Steven ; Augustson, Bradley ; Biccler, Jorne ; Connors, Joseph M. ; Scott, David W. ; Gandhi, Maher K. ; Savage, Kerry J. ; El-Galaly, Tarec ; Villa, Diego ; Cheah, Chan Yoon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Lymphoid Neoplasia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barraclough, Allison</creatorcontrib><creatorcontrib>Alzahrani, Musa</creatorcontrib><creatorcontrib>Ettrup, Marianne Schmidt</creatorcontrib><creatorcontrib>Bishton, Mark</creatorcontrib><creatorcontrib>van Vliet, Chris</creatorcontrib><creatorcontrib>Farinha, Pedro</creatorcontrib><creatorcontrib>Gould, Clare</creatorcontrib><creatorcontrib>Birch, Simone</creatorcontrib><creatorcontrib>Sehn, Laurie H.</creatorcontrib><creatorcontrib>Sovani, Vishakha</creatorcontrib><creatorcontrib>Ward, Mitchell Steven</creatorcontrib><creatorcontrib>Augustson, Bradley</creatorcontrib><creatorcontrib>Biccler, Jorne</creatorcontrib><creatorcontrib>Connors, Joseph M.</creatorcontrib><creatorcontrib>Scott, David W.</creatorcontrib><creatorcontrib>Gandhi, Maher K.</creatorcontrib><creatorcontrib>Savage, Kerry J.</creatorcontrib><creatorcontrib>El-Galaly, Tarec</creatorcontrib><creatorcontrib>Villa, Diego</creatorcontrib><creatorcontrib>Cheah, Chan Yoon</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barraclough, Allison</au><au>Alzahrani, Musa</au><au>Ettrup, Marianne Schmidt</au><au>Bishton, Mark</au><au>van Vliet, Chris</au><au>Farinha, Pedro</au><au>Gould, Clare</au><au>Birch, Simone</au><au>Sehn, Laurie H.</au><au>Sovani, Vishakha</au><au>Ward, Mitchell Steven</au><au>Augustson, Bradley</au><au>Biccler, Jorne</au><au>Connors, Joseph M.</au><au>Scott, David W.</au><au>Gandhi, Maher K.</au><au>Savage, Kerry J.</au><au>El-Galaly, Tarec</au><au>Villa, Diego</au><au>Cheah, Chan Yoon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2019-07-09</date><risdate>2019</risdate><volume>3</volume><issue>13</issue><spage>2013</spage><epage>2021</epage><pages>2013-2021</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearrangements are associated with inferior outcomes. It is unclear whether these variables remain prognostic in stage I/II patients. In this retrospective study, we evaluated the prognostic impact of cell of origin (COO), as well as dual-expressor (DE) status and molecular double-hit (DH) status, in stage I/II DLBCL by positron emission tomography with computed tomography (PET-CT). A total of 211 patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimens, with or without radiotherapy, was included. The median follow-up in the entire cohort was 4 years (range, 0.4-9.4), with estimated 4-year progression-free survival (PFS) and overall survival (OS) rates of 85% (95% confidence interval [CI], 79-89) and 88% (95% CI, 83-92), respectively. By univariable analysis, DE (PFS: hazard ratio [HR], 1.27; 95% CI, 0.58-2.81, P = .55 and OS: HR, 1.40; 95% CI, 0.60-3.30; P = .44), DH (PFS: HR, 1.21; 95% CI, 0.27-5.31; P = .80 and OS: HR, 0.61; 95% CI, 0.08-4.73; P = .64), and non-GCB status (PFS: HR, 1.59; 95% CI, 0.83-3.03; P = .16 and OS: HR, 1.80; 95% CI, 0.89-3.67; P = .10) were associated with poorer outcomes. In patients with PET-CT–defined stage I/II DLBCL treated with R-CHOP–like therapy, with or without radiation, COO and DE and DH status were not significantly associated with inferior PFS or OS. •In early-stage DLBCL, COO and DE/DH status may not confer an inferior prognosis.•Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year PFS and OS rates of 85% and 88%. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31285189</pmid><doi>10.1182/bloodadvances.2019000251</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4625-3009</orcidid><orcidid>https://orcid.org/0000-0003-1000-5393</orcidid><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0002-4406-380X</orcidid><orcidid>https://orcid.org/0000-0001-9364-9391</orcidid><orcidid>https://orcid.org/0000-0001-6058-1036</orcidid><orcidid>https://orcid.org/0000-0002-3043-9503</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2473-9529
ispartof Blood advances, 2019-07, Vol.3 (13), p.2013-2021
issn 2473-9529
2473-9537
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4ba1f4d6c89a4639a9f66dedff959652
source ScienceDirect (Online service); PubMed Central
subjects Lymphoid Neoplasia
title COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COO%20and%20MYC/BCL2%20status%20do%20not%20predict%20outcome%20among%20patients%20with%20stage%20I/II%20DLBCL:%20a%20retrospective%20multicenter%20study&rft.jtitle=Blood%20advances&rft.au=Barraclough,%20Allison&rft.date=2019-07-09&rft.volume=3&rft.issue=13&rft.spage=2013&rft.epage=2021&rft.pages=2013-2021&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2019000251&rft_dat=%3Cproquest_doaj_%3E2254506935%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c545t-3f9972e5567fce9c3cc7c4055101490c1da37f0f8d82b58a647683a6e57539183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2254506935&rft_id=info:pmid/31285189&rfr_iscdi=true